摘要
Non-alcoholic fatty liver disease (NAFLD) is a progressive condition of the liver encompassing a range of pathologies including steatosis, non-alcoholic steatohepatitis (NASH), cirrhosis, and hepatocellular carcinoma. Research into this disease is imperative due to its rapid growth in prevalence, economic burden, and current lack of FDA approved therapies. NAFLD involves a highly complex etiology that calls for multi-tissue multi-omics network approaches to uncover the pathogenic genes and processes, diagnostic biomarkers, and potential therapeutic strategies. In this review, we first present a basic overview of disease pathogenesis, risk factors, and remaining knowledge gaps, followed by discussions of the need and concepts of multi-tissue multi-omics approaches, various network methodologies and application examples in NAFLD research. We highlight the findings that have been uncovered thus far including novel biomarkers, genes, and biological pathways involved in different stages of NAFLD, molecular connections between NAFLD and its comorbidities, mechanisms underpinning sex differences, and druggable targets. Lastly, we outline the future directions of implementing network approaches to further improve our understanding of NAFLD in order to guide diagnosis and therapeutics.
学科与关键词
- Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic testsMasoodi, Mojgan*; Gastaldelli, Amalia; Hyotylainen, Tuulia; Arretxe, Enara; Alonso, Cristina; Gaggini, Melania; Brosnan, Julia; Anstee, Quentin M.; Millet, Oscar; Ortiz, Pablo; Mato, Jose M.; Dufour, Jean-Francois; Oresic, Matej*Nature Reviews. Gastroenterology and Hepatology, 2021, 18(12): 835-856.被引 236
- Multiomics biomarkers for the prediction of nonalcoholic fatty liver disease severityPirola, Carlos J.; Sookoian, Silvia*WORLD JOURNAL OF GASTROENTEROLOGY, 2018, 24(15): 1601-1615.被引 51
- Current insights in molecular characterization of non-alcoholic fatty liver disease and treatmentChe, Wensheng; Zhao, Ming; Li, Xiaoqing; Li, Chunlong*; Cho, William C.*; Yu, Shan*Frontiers in Endocrinology, 2022, 13: 1002916.被引 2
